Truist on Bristol-Myers Squibb Co. (BMY): 'Cobenfy Failure in ARISE Likely to Pressure Shares'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $65.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
